Patents Issued in May 8, 2014
-
Publication number: 20140127162Abstract: According to some embodiments herein, expression systems and methods for reversible gene expression are provided. In some embodiments, adeno-associated viral vectors encoding a gene product of interest and comprising a plurality of recombinase target sites are provided. In some embodiments, a source of recombinase is provided. In some embodiments, the gene product of interest is expressed, and the recombinase then induces recombination events between the recombinase target sites, thus reducing or eliminating expression of the gene product of interest.Type: ApplicationFiled: October 30, 2013Publication date: May 8, 2014Applicant: California Institute of TechnologyInventors: Alejandro Benjamin Balazs, David Baltimore
-
Publication number: 20140127163Abstract: Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Shivalingappa Kottur Swamynathan, Sudha Swamynathan, Kristine-Ann Gallegos Buela, Robert Lee Hendricks
-
Publication number: 20140127164Abstract: Selected bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia are described. In particular, a food composition or supplement product or medical device or pharmaceutical composition has said bacterial strains in association with sterols or phytosterols and/or stanols or phytostanols and/or glucomannan and/or konjac gum and/or prebiotic fibres and/or fermented red rice and/or betaglucans from oats, oat bran, barley, barley bran and/or aloe arborescens gel in lyophilized form.Type: ApplicationFiled: May 9, 2012Publication date: May 8, 2014Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna
-
Publication number: 20140127165Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A is a 6-membered aromatic ring containing carbon atoms and 0-3 nitrogen atoms as ring members, said ring optionally substituted with 1-5 substituents independently selected from R2; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R21; R21 is independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, CN or NO2; and Q is as defined in the disclosure.Type: ApplicationFiled: January 6, 2014Publication date: May 8, 2014Applicant: E.I. du Pont de Nemours and CompanyInventors: George Philip Lahm, Ty Wagerle, Ming Xu
-
Publication number: 20140127166Abstract: The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalizing plasma glucose concentration and/or increasing insulin sensitivity.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: NESTEC S.A.Inventors: Seppo Salminen, Erika Isolauri, Kirsi Laitinen
-
Publication number: 20140127167Abstract: The antifungal mixture is designed for fighting human diseases and animal diseases of fungal, bacterial or other origin and for violation of bio-films on heterogeneous materials used both in human and veterinary medicine and for elimination of microflora from various objects coming in contact with humans or animals. The antifungal mixture uses the active component of the fungal organism Pythium oligandrum in the mixture with inert components; the said antifungal mixture contains 0.001 to 25 weight portions of the fungal organism Pythium oligandrum and 75 to 99.999 weight portions of inert components. The activity of the fungal organism Pythium oligandrum in the mixture arises at the moment when this organism gets in touch with humidity.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: BIO AGENS RESEARCH AND DEVELOPMENT - BARD, s.r.o.Inventors: Martin SUCHÁNEK, Radim KLIMES
-
Publication number: 20140127168Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.Type: ApplicationFiled: May 4, 2011Publication date: May 8, 2014Applicant: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20140127169Abstract: The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues.Type: ApplicationFiled: January 24, 2012Publication date: May 8, 2014Applicants: UNIVERSITE DE STRASBOURG, STOWERS INSTITUTE FOR MEDICAL RESEARCH, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIESInventors: Olivier Pourquie, Matthias Wahl, Jerome Chal
-
Publication number: 20140127170Abstract: A chimeric skin comprising immortalized human keratinocyte cells cocultured with donor keratinocytes is disclosed.Type: ApplicationFiled: October 31, 2013Publication date: May 8, 2014Applicant: Wisconsin Alumni Research FoundationInventor: B. Lynn Allen-Hoffmann
-
Publication number: 20140127171Abstract: Methods of treating chronic post-traumatic encephalopathy (PTE) using regenerative approaches is described. In one embodiment, molecules with capability of stimulating endogenous neural stem cells is provided. In another embodiment, cell therapeutics are provided capable of addressing angiogenic deficits in patients suffering from PTE. In another embodiment, cells are utilized to induce activation of endogenous progenitor cells in the central nervous system of PTE patients. Furthermore, low level laser irradiation is disclosed as a means of treatment of PTE either through direct administration to CNS tissue for stimulation of endogenous progenitor cells and reparative processes, or together with administration of exogenous stem cells, whether autologous or allogeneic. In a further embodiment exogenous stem cells are pretreated with laser prior to administration.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Inventors: Roger Nocera, James Eaker
-
Publication number: 20140127172Abstract: A method of preserving functionality of an organ is disclosed herein, including removing a whole organ including vasculature from a donor, cryo-preserving the whole organ including vasculature, thawing the whole organ including vasculature so that at least a portion of cells contained therein resume biological activity, and introducing the whole organ including vasculature into a recipient so that a blood vessel in the vasculature is supplied with blood. Further disclosed herein is a method of preserving fertility of a patient undergoing a treatment expected to cause sterility, including removing at least one whole gonadal organ including vasculature from the patient, preserving functionality of the gonadal organ as described herein, conducting the treatment and waiting for an effect thereof to subside, and introducing the gonadal organ into the patient.Type: ApplicationFiled: November 8, 2013Publication date: May 8, 2014Inventors: Amir ARAV, Yehudit NATAN, Saar YAVIN, Uri MEIR, Udi DAMARI
-
Publication number: 20140127173Abstract: This invention relates to the production of populations of Smooth Muscle Cells (SMCs) of specific embryonic lineages, such as neuroectodermal and mesodermal SMCs. Pluripotent stem cells are cultured in one or more lineage induction media to produce progenitor cells of a defined embryonic lineage, which are then cultured in an SMC induction medium to produce a population of SMCs of the embryonic lineage. Populations of SMCs of defined lineages may be useful, for example, in in accurately modelling vascular disease.Type: ApplicationFiled: June 13, 2012Publication date: May 8, 2014Applicant: Cambridge Enterprise LimitedInventors: Sanjay Sinha, Roger Pedersen, Andreia Bernardo, Christine Cheung
-
Publication number: 20140127174Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: January 7, 2014Publication date: May 8, 2014Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne D. Larsen, Jens R. Daugaard, Trine S. R. Neerup
-
Publication number: 20140127175Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: January 7, 2014Publication date: May 8, 2014Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Publication number: 20140127176Abstract: The present invention relates to compositions and methods for preventing and treating periodontitis and other conditions. In particular, the present invention relates to oral bacteria for use in treating and preventing diseases and conditions.Type: ApplicationFiled: March 2, 2012Publication date: May 8, 2014Applicants: TUFTS MEDICAL CENTER, TUFTS UNIVERSITYInventors: Linden Hu, Brian A. Klein, Elizabeth Tenorio
-
Publication number: 20140127177Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: November 1, 2013Publication date: May 8, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20140127178Abstract: The invention relates to the use of a microbial composition for the simultaneous reduction of important animal waste parameters, such as ammonia emission, the dry matter content, and amount of nitrogen, the amount of ammonium, and the amount of phosphorus present in the animal waste. It further relates to a method for the simultaneous reduction of important animal waste parameters, such as ammonia emission, the dry matter content, and amount of nitrogen, the amount of ammonium, and the amount of phosphorus present in the animal waste; comprising administering a microbial composition to an animal.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Inventor: Michael Athanasius Olde Dubbelink
-
Publication number: 20140127179Abstract: A formulation of supplement is able to boost the natural cells, both increasing the population of the natural cells and enhancing the natural cell's activity. The formulation can be administered via different forms, such as tablet, injection, skin absorption and etc. This formulation comprises 16 different components, including Alpha Lipoic Acid, Arabinoxylin, Curcumin, Garlic, Genistein, Ginseng, Lentinan, Mistletoe, N-Acetylcysteine, Resveratrol, Selenium, Vitamin B Complex, Vitamin C, Vitamin D3, Vitamin E and Zinc. By virtue of enhancing the natural killer cells (NKC) in the body, the formation is helpful for the prevention and treatment of a number of different human or animal diseases, such as cancers and viral infections. In addition, certain synergistic effects have been observed between different components in the formulation, which further enhances the beneficial effect of the formulation.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Applicant: SCIENTIFIC FORMULATIONS, LLCInventor: Jerry Thomas THORNTHWAITE
-
Publication number: 20140127180Abstract: The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.Type: ApplicationFiled: May 4, 2012Publication date: May 8, 2014Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Isabelle De Waziers, Walid Touati, Monique Diry, Jean-Pierre Flinois, Patrick Dansette, Philippe Beaune
-
Publication number: 20140127181Abstract: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.Type: ApplicationFiled: December 10, 2013Publication date: May 8, 2014Applicant: Novo Nordisk HealthCare A/GInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20140127182Abstract: The present invention relates to a use of Glycine N-methyltransferase (GNMT) in treating or preventing fatty liver related disease, such as nonalcoholic fatty liver disease (NAFLD) or hepatocellular carcinoma (HCC). The use of GNMT for treating or preventing fatty liver diseases is achieved by enhancing GNMT-NPC2 interaction, and thus decreasing or preventing the accumulation of lipid and cholesterol in hepatic cells or tissues.Type: ApplicationFiled: May 9, 2013Publication date: May 8, 2014Applicant: National Yang-Ming UniversityInventors: Yi-Ming CHEN, Chia-Hung YEN, Yi-Jen LIAO, Kuan-Hsuan CHEN
-
Publication number: 20140127183Abstract: Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2).Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: The Scripps Research InstituteInventors: Paul SCHIMMEL, Keisuke WAKASUGI
-
Publication number: 20140127184Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.Type: ApplicationFiled: April 20, 2012Publication date: May 8, 2014Applicant: CUREMARK, LLCInventors: Joan Fallon, Matthew Heil, James Szigethy, James Fallon
-
Publication number: 20140127185Abstract: Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as progesterone or allopregnanolone, and a thrombolytic agent, such as tissue plasminogen activator (tPA). Also described are compositions and methods for reducing the risks of thrombolytic agent treatment using a neuroprotective steroid.Type: ApplicationFiled: October 31, 2013Publication date: May 8, 2014Applicant: Emory UniversityInventors: Donald G. Stein, Iqbal Sayeed
-
Publication number: 20140127186Abstract: The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients.Type: ApplicationFiled: June 26, 2012Publication date: May 8, 2014Inventor: Sang Duck Kim
-
Publication number: 20140127187Abstract: Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Applicant: Nitto Denko CorporationInventors: Yoshiro Niitsu, Rishu Takimoto
-
Publication number: 20140127188Abstract: Embodiments of the invention include methods and compositions for treatment of adipose deposits.Type: ApplicationFiled: July 19, 2012Publication date: May 8, 2014Inventors: Katherine Cernok, Kenneth Martinez
-
Publication number: 20140127189Abstract: Provided is a composition for preventing or alleviating skin wrinkles containing honeybush (Cyclopia intermedia) extract, a fraction thereof, or a fermented honeybush as an active ingredient. More particularly, the honeybush extract or fermented honeybush of the claimed subject matter can reduce the length and depth of skin wrinkles caused by UV irradiation and reduce the thickness of the epidermal layer, in addition to suppress collagen tissue breakdown reactions, indicating it is excellent in alleviating skin wrinkles, so that it can be effectively used as an active ingredient of a composition for preventing or alleviating skin wrinkles.Type: ApplicationFiled: July 11, 2012Publication date: May 8, 2014Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINEInventors: Sungwook Chae, Hwa-Jung Choi, Jae-Hyoung Song, Goya Choi, Mi Young Lee
-
Publication number: 20140127190Abstract: Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jordan Marshall Sand, Mark Eric Cook, Daniel Elmer Butz
-
Publication number: 20140127191Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.Type: ApplicationFiled: May 14, 2013Publication date: May 8, 2014Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
-
Publication number: 20140127192Abstract: The invention is directed to a method for increasing bone mineral density (BMD) in a postmenopausal woman. The method comprises administering to a postmenopausal woman having a lumbar vertebrae T-score of less than or equal to ?2 an anti-sclerostin antibody in an amount and for a time effective to increase lumbar vertebrae BMD at least about 9% from pretreatment baseline at twelve months following initial anti-sclerostin antibody administration. The invention also is directed to a method for treating osteoporosis. The method comprising administering to a postmenopausal woman with osteoporosis an anti-sclerostin antibody in an amount of about 70 mg to about 210 mg at once a month, optionally for about three to about 18 months. Alternatively, the method comprises administering an anti-sclerostin antibody in an amount of about 140 mg to about 210 mg every three months, optionally about six to about 18 months.Type: ApplicationFiled: April 18, 2012Publication date: May 8, 2014Applicant: AMGEN INCInventors: Javier San Martin, Scott Wasserman
-
Publication number: 20140127193Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.Type: ApplicationFiled: May 7, 2012Publication date: May 8, 2014Applicant: DUKE UNIVERSITYInventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
-
Publication number: 20140127194Abstract: The invention relates to the use deuterium depleted water (DDW) for the preparation of combined pharmaceutical compositions for the prevention or treatment of tumorous diseases, where the composition comprises DDW with deuterium content of 0.01 to 135 ppm and one or more antineoplastic agent(s), optionally together with one or more usual pharmaceutical auxiliary material(s). Further, the invention relates to pharmaceutical compositions for adjuvant treatment of tumorous diseases, where the composition comprises DDW with deuterium content of 0.01 to 135 ppm and one or more antineoplastic agent(s), optionally together with one or more usual pharmaceutical auxiliary material(s). The invention also relates to aqueous pharmaceutical compositions usually applied in curing where the aqueous component is DDW with deuterium content of 0.01 to 135 ppm.Type: ApplicationFiled: June 1, 2012Publication date: May 8, 2014Inventor: Gábor Somlyai
-
Publication number: 20140127195Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Jane K. Relton, Roy R. Lobb, Eric T. Whalley, Steve P. Adams
-
Publication number: 20140127196Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Publication number: 20140127197Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.Type: ApplicationFiled: February 6, 2013Publication date: May 8, 2014Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Publication number: 20140127198Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: ApplicationFiled: August 26, 2013Publication date: May 8, 2014Applicant: Baylor Research InstituteInventors: Gerard Zurawski, Jacques Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
-
Publication number: 20140127199Abstract: The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and/or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders.Type: ApplicationFiled: November 24, 2010Publication date: May 8, 2014Applicant: The United States of America,as represented by the Secretary, Department of Health & Human ServicesInventors: Juan Rivera, Nicolas Charles
-
Publication number: 20140127200Abstract: Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.Type: ApplicationFiled: October 15, 2013Publication date: May 8, 2014Applicant: The Scripps Research InstituteInventor: Carlos F. Barbas, III
-
Publication number: 20140127201Abstract: Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities.Type: ApplicationFiled: October 25, 2013Publication date: May 8, 2014Inventors: Shapiro Leland, Eli C. Lewis, Charles A. Dinarello
-
Publication number: 20140127202Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.Type: ApplicationFiled: January 13, 2014Publication date: May 8, 2014Applicant: Aventis Pharma S.A.Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
-
Publication number: 20140127203Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: March 15, 2013Publication date: May 8, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
-
Publication number: 20140127204Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.Type: ApplicationFiled: March 22, 2013Publication date: May 8, 2014Applicant: NovelMed Therapeutics, Inc.Inventor: NovelMed Therapeutics, Inc.
-
Publication number: 20140127205Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.Type: ApplicationFiled: June 20, 2013Publication date: May 8, 2014Applicant: Queen Mary & Westfield CollegeInventors: Gavin Paul Vinson, Stewart Barker, John Richard Puddefoot
-
Publication number: 20140127206Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: ApplicationFiled: December 19, 2013Publication date: May 8, 2014Applicant: ZYMOGENETICS, INC.Inventors: YUE YAO, JANINE BILSBOROUGH
-
Publication number: 20140127207Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.Type: ApplicationFiled: January 3, 2014Publication date: May 8, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
-
Publication number: 20140127208Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Publication number: 20140127209Abstract: The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.Type: ApplicationFiled: March 8, 2013Publication date: May 8, 2014Inventors: Kenneth GRABSTEIN, William BRADY, Gordon KING, Natalie Winblade NAIRN, Kurt David SHANEBECK, Paul Heffner SLAGLE, Kenneth Christopher THORNTON, Michael Peter VANBRUNT, Andrea WANG, Hengyu XU
-
Publication number: 20140127210Abstract: A bispecific antigen binding protein complex comprising a first polypeptide comprising a first antigen binding site at an N terminus; a second polypeptide comprising a second antigen binding site at an N terminus; and a linker connecting the first polypeptide and the second polypeptide; wherein the linker comprises a tag at one terminus thereof, and wherein the tag is connected to a C-terminus of the first polypeptide or to an N-terminus of the second polypeptide, and comprises a cleavable amino acid sequence; as well as related compositions and methods.Type: ApplicationFiled: October 31, 2013Publication date: May 8, 2014Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: MIN-KYUNG KIM, JUNGWOOK LEE, SUJEONG HWANG, JAEIL LEE
-
Publication number: 20140127211Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: November 6, 2013Publication date: May 8, 2014Applicant: Pfizer Inc.Inventors: Kenneth G. Geles, Yijie Gao, Puja Sapra, Lioudmila Gennadievna Tchistiakova, Bin-Bing Stephen Zhou
